Skip to main content

Table 1 Poisson regression analysis assessing the relationship between Euro-GASP versus national antimicrobial susceptibility data to azithromycin, cefixime and ciprofloxaxin by country and overall, 2009 to 2013

From: The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area

Ā 

Azithromycin

Cefixime

Ciprofloxacin

Source b

Country

IRR

P value

CI-lower

CI-upper

No. of tests/years

IRR

P value

CI-lower

CI-upper

No. of tests/years

IRR

P value

CI-lower

CI-upper

No. of tests/years

Austria

0.138

<ā€‰0.0001

0.085

0.224

3456/4

0.052

<ā€‰0.0001

0.03

0.089

3454/4

1.000

0.995

0.885

1.129

3456/4

1

Belgium

0.68

0.079

0.442

1.046

3198/5

0.065

<ā€‰0.0001

0.18

0.241

1919/3

0.973

0.659

0.863

1.098

3198/5

1

Denmark

No national azithromycin susceptibility data available

No national cefixime susceptibility data available

1.006

0.923

0.895

1.131

2811/5

1

France

No national azithromycin susceptibility data available

0.871

0.747

0.375

2.019

5626/4

0.913

0.251

0.781

1.067

5628/4

2

Germany

6.085

0.083

0.791

46.79

321/1

Model not performed - too few positive isolates

1.447

0.018

1.064

1.968

321/1

2

Greece

1.078

0.781

0.634

1.832

425/3

1.282

0.415

0.705

2.331

505/3

1.008

0.917

0.87

1.167

1053/5

1

Hungary

Model not performed - too few positive isolates

Model not performed - too few positive isolates

0.98

0.839

0.803

1.194

776/3

2

Italy

0.944

0.794

0.615

1.451

1144/4

0.863

0.537

0.539

1.38

1170/4

1.003

0.972

0.859

1.171

1134/4

1

Malta

No resistant isolates

Ā Ā 

No national cefixime susceptibility data available

1.004

0.983

0.708

1.424

219/4

1

The Netherlands

2.23

0.003

1.324

3.757

4440/3

No national cefixime susceptibility data available

1.097

0.133

0.972

1.237

7695/5

2

Norway

1.389

0.152

0.886

2.177

594/2

2.22

0.037

1.051

4.687

594/2

1.063

0.596

0.848

1.334

594/2

1

Slovakia

No national azithromycin susceptibility data available

0.921

0.883

0.309

2.748

325/1

1.112

0.527

0.801

1.544

325/1

1

Slovenia

1.434

0.287

0.739

2.781

377/5

1.219

0.527

0.66

2.253

377/5

0.987

0.92

0.762

1.277

377/5

1

Sweden

1.818

0.002

1.252

2.638

4158/5

2.005

0.006

1.225

3.281

4158/5

0.956

0.459

0.849

1.077

4158/5

1

The United Kingdom

0.83

0.554

0.448

1.538

8154/5

1.706

0.042

1.02

2.852

8154/5

1.013

0.825

0.903

1.136

8154/5

1

All countries - univariate

ā€ƒSystema

1.09

0.269

0.935

1.271

26,267

0.863

0.101

0.724

1.029

26,282

1.008

0.697

0.969

1.049

39,889

Ā 

ā€ƒSourceb

0.98

0.977

0.227

4.217

26,267

0.248

0.121

0.043

1.443

26,282

0.838

0.209

0.637

1.104

39,889

Ā 
  1. aSystemā€‰=ā€‰Euro-GASP data (1) vs. national data (2)
  2. bSourceā€‰=ā€‰Source of comparison data; all data from Euro-GASP laboratory (1) vs. part or no data from Euro-GASP laboratory (2)
  3. IRR incidence-rate ratio, CI 95% confidence interval. Significant values (<ā€‰0.05) in bold
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us